San Diego, CA. USA (UroToday.com) – Coming off the recent FDA approval of Flucicovine F18 (FACBC), trade name Axumin®, it was with obvious excitement the CEO of Blue Earth Diagnostics discussed the research which lead to the recent news. Flucicovine is a synthetic amino acid based PET agent, which has been approved in men with suspected prostate cancer recurrence based on elevated PSA. Jonathan Allis, D. Phil Biochemistry, CEO of Blue Earth Diagnostics Ltd. in Burlington, MA presented the data at the 2016 Society of Nuclear Medicine and Molecular Imaging Conference.